作者
Salim Yusuf,Jackie Bosch,Gilles R. Dagenais,Jun Zhu,Denis Xavier,Lisheng Liu,Prem Pais,Patricio Lopez-Jaramillo,Itamar Raz,Antonio L. Dans,Alvaro Avezum,Leopoldo S. Piegas,Alexander Parkhomenko,Katalin Keltai,Matyas Keltai,Karen Sliwa,Robert Peters,Claes Held,Irina Chazova,Khalid Yusoff,Basil S. Lewis,Petr Jansky,Kamlesh Khunti,William D. Toff,Christopher M. Reid,John Varigos,Gregorio Sanchez-Vallejo,Robert S. McKelvie,Janice Pogue,Hyejung Jung,Peggy Gao,Rafael Diaz,Eva Lonn,Hope Investigators
摘要
Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease.